FGF2 induces imatinib resistance in patients’ CD34+ CML cells via reactivation of FGFR3-RAS-MAPK signaling (Traer et al., 2014). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.